Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951149 | 1.00 | TP53 (0.39) | TP53ALOX15ALDH1A1CA12CA1 | |
| Hydrochloric Acid SCHEMBL2212116 | 0.98 | TP53 (0.38) | TP53ALOX15ALDH1A1CA12CA1 | |
| Hydrochloric Acid SCHEMBL2212113 | 0.98 | TP53 (0.38) | TP53ALOX15ALDH1A1CA12CA1 | |
| SCHEMBL6433997 | 0.84 | TP53 (0.37) | TP53ALDH1A1CA1CA2LMNA | |
| SCHEMBL27594511 | 0.82 | ALOX15 (0.38) | TP53ALOX15ALDH1A1CA12CA1 | |
| SCHEMBL20528273 | 0.82 | TP53 (0.38) | TP53ALOX15ALDH1A1CA12CA1 | |
| SCHEMBL27594510 | 0.82 | ALOX15 (0.38) | TP53ALOX15ALDH1A1CA12CA1 | |
| SCHEMBL3766175 | 0.81 | CA14 (0.39) | TP53ALDH1A1CA12CA1CA2 | |
| SCHEMBL1786590 | 0.81 | CA14 (0.39) | TP53ALDH1A1CA12CA1CA2 | |
| SCHEMBL1786589 | 0.81 | CA14 (0.39) | TP53ALDH1A1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100360502-C | Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents | ARDENIA INVESTMENTS LTD (GB) | 2008-01-09 | — | — | CN | claimed |
| CN-1668583-A | Retinol derivatives, their use in the treatment of cancer and for enhancing the efficacy of other cytotoxic agents | ARDENIA INVESTMENTS LTD (GB) | 2005-09-14 | — | — | CN | claimed |
| CN-111920967-B | Technetium [ 99m Tc]Double-cysteine ethyl ester injection and marking process thereof | 北京森科医药有限公司 | 2023-04-28 | — | — | CN | disclosed |
| EP-3386947-B1 | METHOD FOR PRODUCING N-RETINOYLAMINOALKANE SULFONIC ACID | OASMIA PHARMACEUTICAL AB (SE) | 2021-05-19 | — | — | EP | disclosed |
| US-10322996-B2 | Method for producing N-retinoylcysteic acid alkyl ester | ARDENIA INVESTMENTS, LTD (GB) | 2019-06-18 | — | — | US | disclosed |
| US-20190127322-A1 | METHOD FOR PRODUCING N-RETINOYLCYSTEIC ACID ALKYL ESTER | VIVESTO AB (SE) | 2019-05-02 | — | — | US | disclosed |
| US-10138204-B2 | Method for producing N-retinoylcysteic acid alkyl ester | ARDENIA INVESTMENTS, LTD (GB) | 2018-11-27 | — | — | US | disclosed |
| US-20180290973-A1 | METHOD FOR PRODUCING N-RETINOYLCYSTEIC ACID ALKYL ESTER | VIVESTO AB (SE) | 2018-10-11 | — | — | US | disclosed |
| CN-100360502-C | Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents | ARDENIA INVESTMENTS LTD (GB) | 2008-01-09 | — | — | CN | disclosed |
| CN-1668583-A | Retinol derivatives, their use in the treatment of cancer and for enhancing the efficacy of other cytotoxic agents | ARDENIA INVESTMENTS LTD (GB) | 2005-09-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127322-A1 | METHOD FOR PRODUCING N-RETINOYLCYSTEIC ACID ALKYL ESTER | AHCY, LRAT, RARA | TP53 3450/4885ALOX15 237/4885ALDH1A1 225/4885 |
| US-20180290973-A1 | METHOD FOR PRODUCING N-RETINOYLCYSTEIC ACID ALKYL ESTER | AHCY, LRAT, RARA | TP53 3450/4885ALOX15 237/4885ALDH1A1 225/4885 |
| US-10138204-B2 | Method for producing N-retinoylcysteic acid alkyl ester | AHCY, LRAT, RARA | TP53 3450/4885ALOX15 237/4885ALDH1A1 225/4885 |
| US-10322996-B2 | Method for producing N-retinoylcysteic acid alkyl ester | AHCY, LRAT, RARA | TP53 3450/4885ALOX15 237/4885ALDH1A1 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.